^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    BeiGene Press Release
    Title:

    BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

    Published date:
    12/07/2020
    Excerpt:
    BeiGene...today announced that the China National Medical Products Administration (NMPA) has approved BLINCYTO (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    ...for patients with R/R Ph-negative precursor B-cell ALL, recommended category 1 options include blinatumomab or InO.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASH 2020
    Title:

    268 Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial

    Published date:
    11/04/2020
    Excerpt:
    Blinatumomab reduced the risk of relapse by 64% vs HC3 (hazard ratio 0.36, 95% confidence interval [CI] 0.19-0.66, p < 0.001). In addition, OS favored blinatumomab vs HC3 (hazard ratio 0.43, 95% CI 0.18-1.01)...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    N Engl J Med
    Title:

    Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Excerpt:
    Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor ALL.
    DOI:
    10.1056/NEJMoa1609783
    Trial ID:
    TOWER